GSK Puts $1.4B on the Line in Aiolos Acquisition to Boost Asthma Pipeline

Following in the footsteps of Novartis, J&J and Merck, GSK jumped into the J.P. Morgan dealmaking frenzy Tuesday, picking up respiratory and inflammation-focused Aiolos Bio.